2-(二甲基氨基)-4-吡啶基-硼酸 | 1207749-70-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-(二甲基氨基)-4-吡啶基-硼酸
• 英文名称: (2-(dimethylamino)pyridin-4-yl)boronic acid
• 英文别名: [2-(dimethylamino)pyridin-4-yl]boronic acid
• CAS: 1207749-70-9
• 化学式: C₇H₁₁BN₂O₂
• 分子量: 165.988
• InChiKey: UEJBHXVBUABNEO-UHFFFAOYSA-N

物化性质

• 沸点：
  367.6±52.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.17
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  56.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  双(4-氯苯基)二硒化物 、 2-(二甲基氨基)-4-吡啶基-硼酸 在 MCM-41 immobilized bipyridine copper(I) complex 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 14.0h， 以81%的产率得到4-chlorophenyl(6-dimethylamino-3-pyridyl)selenide
  参考文献：
  名称：

  高效且可重复使用的MCM-41固定联吡啶铜（i）催化剂，用于有机硼酸与二芳基二硒化物的C-Se偶联†

  摘要：

  A高效MCM-41固定联吡啶铜（我）络合物[MCM-41联吡啶翠]从4,4'-双[3-（三乙氧基硅基）丙基氨基] -2,2'-联吡啶制备通过固定上介孔材料MCM-41，然后与CuI反应。在5 mol％MCM-41-bpy-CuI的存在下，有机硼酸与二芳基二硒化物的交叉偶联反应在DMSO / H 2 O（2/1）中于110°C的空气中顺利进行，得到了多种二有机基硒化物，收率好至极好。可以通过简单过滤反应溶液来回收和再循环这种多相铜催化剂，并在不降低活性的情况下，至少进行了10次连续试验。

  DOI：

  10.1039/c4nj01687d
• 作为产物：
  描述：

  4-溴-N,N-二甲基吡啶-2-胺 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 、 三环己基膦 作用下， 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以100%的产率得到2-(二甲基氨基)-4-吡啶基-硼酸
  参考文献：
  名称：

  [EN] HPK1 ANTAGONISTS AND USES THEREOF
  [FR] ANTAGONISTES DE HPK1 ET LEURS UTILISATIONS

  摘要：

  本发明提供了化合物，其组成物以及使用它们来抑制HPK1和治疗HPK1介导的疾病的方法。

  公开号：

  WO2022187856A1

文献信息

• [EN] SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS<br/>[FR] ANALOGUES D'URÉE PONTÉS SUBSTITUÉS EN TANT QUE MODULATEURS DE SIRTUINE
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016079709A1

  公开（公告）日：2016-05-26

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

  本发明涉及一种新型的取代桥式脲类似物化合物，其化学式为（I）或其药学上可接受的盐，相应的药物组合物，制备这种化合物的方法以及单独使用或与其他治疗剂联合使用的这些化合物作为Sirtuin调节剂，可用于增加细胞寿命，并用于治疗和/或预防各种疾病和紊乱，包括但不限于与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、血液凝块紊乱、炎症、癌症和/或潮红有关的疾病或紊乱，以及那些会受益于增加线粒体活性的疾病或紊乱。
• PYRIDO FIVE-ELEMENT AROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：SHANGHAI HAIHE PHARMACEUTICAL CO., LTD.

  公开号：US20190211010A1

  公开（公告）日：2019-07-11

  The present invention provides a pyrido five-element aromatic ring compound, and a preparation method therefor and a use thereof. The compound provided in the present invention has an inhibitory effect on wild-type and/or mutant EZH2, and is well positioned to become a novel anti-tumor drug or a drug for the treatment of autoimmune diseases.

  本发明提供了一种吡啶五元芳香环化合物，以及其制备方法和用途。本发明提供的化合物对野生型和/或突变型EZH2具有抑制作用，并有望成为一种新型抗肿瘤药物或治疗自身免疫疾病的药物。
• [EN] SUBSTITUTED 1,6-NAPHTHYRIDINES<br/>[FR] 1,6-NAPHTYRIDINES SUBSTITUÉES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014079787A1

  公开（公告）日：2014-05-30

  The present invention relates to the use of compounds of general formula (I) wherein R' is hydrogen or lower alkyl; R1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)-NH-lower alkyl, CH2-C(O)-NH-lower alkyl, CH2-NH-C(O)-lower alkyl, CH2NH2, S(O)2CH3, S(O)2N(CH3)2, or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH3)2; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, NH-S(O)2-CH3, -(CH2)m-O-lower alkyl or -(CH2)n-S(O)2-CH3; or is -(CR2)n-phenyl, optionally substituted by -S(O)2CH3 or lower alkoxy; or is -(CH2)n-heterocycloalkyl, optionally substituted by lower alkyl and =O; or is -(CH2)n-heteroaryl, optionally substituted by one or two lower alkyl groups; or is -(CH2)n-cycloalkyl, optionally substituted by cyano; or R2 and R3 form together with the N atom to which they are attached a heterocyclic ring, selected from morpholine, piperidine, 1, 1-dioxo-thiomorpholine or piperazine which may be substituted by lower alkyl or C(O)O-lower alkyl, or may form a pyrrolidine ring, optionally substituted by hydroxy; R is independently from n hydrogen or lower alkyl; n is 0, 1, 2, 3; m is 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction ("chemobrain"), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及使用一般式（I）的化合物，其中R'是氢或较低的烷基；R1是卤素、较低的烷基、环烷基或氰基；或者是苯基，可选择地被一个到三个取代基取代，所述取代基选自较低的烷基、被卤素取代的较低烷基、较低的烷氧基、被卤素取代的较低烷氧基、卤素、氰基、羟基、C(O)-NH-较低烷基、CH2-C(O)-NH-较低烷基、CH2-NH-C(O)-较低烷基、CH2NH2、S(O)2CH3、S(O)2N(CH3)2，或者是由杂环烷基组成的基团；或者是吡唑-1、4或5-基，可选择地被较低烷基取代；或者是噻唑-5-基，可选择地被一个或两个较低烷基基团取代；或者是吡啶-2、3或4-基，可选择地被较低烷基、较低烷氧基、卤素或N(CH3)2取代；或者是3,6-二氢-2H-吡喃；或者是苯并[d][1,3]二噁嗪-5-基；或者是2,3-二氢苯并[b][1,4]二噁烷-6-基；R2是氢、较低烷基或被烷氧基取代的较低烷基；R3是氢、较低烷基、被卤素取代的较低烷基、被羟基取代的较低烷基、NH-S(O)2-CH3、-(CH2)m-O-较低烷基或-(CH2)n-S(O)2-CH3；或者是-(CR2)n-苯基，可选择地被-S(O)2CH3或较低烷氧基取代；或者是-(CH2)n-杂环烷基，可选择地被较低烷基和=O取代；或者是-(CH2)n-杂芳基，可选择地被一个或两个较低烷基基团取代；或者是-(CH2)n-环烷基，可选择地被氰基取代；或者R2和R3与它们连接的N原子一起形成一个杂环环，所述杂环环选自吗啉、哌啶、1,1-二氧代-硫代吗啉或哌嗪，可被较低烷基或C(O)O-较低烷基取代，或者可形成一个吡咯烷环，可选择地被羟基取代；R独立于n是氢或较低烷基；n为0、1、2、3；m为2；或者是药学上可接受的酸盐，或者是外消旋混合物，或者是其对应的对映体和/或光学异构体，用于治疗精神分裂症、强迫性人格障碍、抑郁症、躁郁症、焦虑症、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍（“化疗脑”）、唐氏综合征、自闭症谱系障碍、听力丧失、耳鸣、脊髓小脑共济失调、肌萎缩侧索硬化、多发性硬化症、亨廷顿病、中风，以及由放射治疗、慢性应激、视神经病变或黄斑变性引起的干扰，或者由酒精、阿片类药物、甲基苯丙胺、芬太尼或可卡因等神经活性药物的滥用引起的干扰。
• SUBSTITUTED 1,6-NAPHTHYRIDINES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20150252044A1

  公开（公告）日：2015-09-10

  The present invention relates to the use of compounds of general formula wherein R′ is hydrogen or lower alkyl; R 1 is halogen, lower alkyl, cycloalkyl or cyano; or is phenyl, optionally substituted by one to three substituents, selected from lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, halogen, cyano, hydroxy, C(O)—NH-lower alkyl, CH 2 —C(O)—NH-lower alkyl, CH 2 —NH—C(O)-lower alkyl, CH 2 NH 2 , S(O) 2 CH 3 , S(O) 2 N(CH 3 ) 2 , or by heterocycloalkyl groups; or is pyrazol-1, 4 or 5-yl, optionally substituted by lower alkyl; or is thiazol-5-yl, optionally substituted by one or two lower alkyl groups; or is pyridine 2, 3 or 4-yl, optionally substituted by lower alkyl, lower alkoxy, halogen or N(CH 3 ) 2 ; or is 3,6-dihydro-2H-pyran; or is benzo[d][1,3]dioxol-5-yl; or is 2,3-dihydrobenzo[b][1,4]dioxin-6-yl; R 2 is hydrogen, lower alkyl or lower alkyl substituted by alkoxy; R 3 is hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, NH—S(O) 2 —CH 3 , —(CH 2 ) m —O-lower alkyl or —(CH 2 ) n —S(O) 2 —CH 3 ; or is —(CR 2 ) n -phenyl, optionally substituted by —S(O) 2 CH 3 or lower alkoxy; or is —(CH 2 ) n -heterocycloalkyl, optionally substituted by lower alkyl and ═O; or is —(CH 2 ) n -heteroaryl, optionally substituted by one or two lower alkyl groups; or is —(CH 2 ) n -cycloalkyl, optionally substituted by cyano; or R 2 and R 3 form together with the N atom to which they are attached a heterocyclic ring, selected from morpholine, piperidine, 1,1-dioxo-thiomorpholine or piperazine which may be substituted by lower alkyl or C(O)O-lower alkyl, or may form a pyrrolidine ring, optionally substituted by hydroxy; R is independently from n hydrogen or lower alkyl; n is 0, 1, 2, 3; m is 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, for the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs selected from alcohol, opiates, methamphetamine, phencyclidine or cocaine.

  本发明涉及通式化合物的使用，其中R′为氢或低碳基；R1为卤素，低碳基，环烷基或氰基；或为苯基，可选地被一到三个取代基取代，所述取代基从低碳基，被卤素取代的低碳基，低碳氧基，被卤素取代的低碳氧基，卤素，氰基，羟基，C（O）-NH-低碳基，CH2-C（O）-NH-低碳基，CH2-NH-C（O）-低碳基，CH2NH2，S（O）2CH3，S（O）2N（CH3）2或杂环烷基组成；或为吡唑-1、4或5-基，可选地被低碳基取代；或为噻唑-5-基，可选地被一或两个低碳基取代；或为吡啶2、3或4-基，可选地被低碳基，低碳氧基，卤素或N（CH3）2取代；或为3,6-二氢-2H-吡喃基；或为苯并[d][1,3]二噁英-5-基；或为2,3-二氢苯并[b][1,4]二噁英-6-基；R2为氢，低碳基或被烷氧基取代的低碳基；R3为氢，低碳基，被卤素取代的低碳基，被羟基取代的低碳基，NH-S（O）2-CH3，（CH2）m-O-低碳基或（CH2）n-S（O）2-CH3；或为-（CR2）n-苯基，可选地被-S（O）2CH3或低碳氧基取代；或为-（CH2）n-杂环烷基，可选地被低碳基和═O取代；或为-（CH2）n-杂环芳基，可选地被一或两个低碳基取代；或为-（CH2）n-环烷基，可选地被氰基取代；或R2和R3与它们附着的N原子一起形成一个杂环环，所述杂环环从吗啉，哌啶，1,1-二氧-硫代吗啉或哌嗪中选择，所述杂环环可以被低碳基或C（O）O-低碳基取代，或可以形成一个吡咯烷环，可选地被羟基取代；R独立于n为氢或低碳基；n为0,1,2,3；m为2；或为其相应的对映异构体和/或光学异构体的药学上可接受的酸盐或外消旋体，用于治疗精神分裂症，强迫性人格障碍，抑郁症，双相情感障碍，焦虑症，正常衰老，癫痫，视网膜退化，创伤性脑损伤，脊髓损伤，创伤后应激障碍，恐慌症，帕金森病，痴呆，阿尔茨海默病，轻度认知障碍，化疗引起的认知功能障碍（“化疗脑”），唐氏综合症，自闭症谱系障碍，听力损失，耳鸣，脊髓小脑性共济失调，肌萎缩侧索硬化症，多发性硬化症，亨廷顿病，中风以及由放射治疗，慢性压力，视神经病变或黄斑变性，或滥用酒精，阿片类药物，甲基苯丙胺，苯环利定或可卡因等神经活性药物引起的干扰。
• A highly efficient and reusable MCM-41-immobilized bipyridine copper(<scp>i</scp>) catalyst for the C–Se coupling of organoboronic acids with diaryl diselenides
  作者：Hong Zhao、Yuanyuan Jiang、Qiurong Chen、Mingzhong Cai

  DOI：10.1039/c4nj01687d

  日期：——

  A highly efficient MCM-41-immobilized bipyridine copper(I) complex [MCM-41-bpy-CuI] was prepared from 4,4′-bis[3-(triethoxysilyl)propylaminomethyl]-2,2′-bipyridine via immobilization on the mesoporous material MCM-41, followed by reaction with CuI. In the presence of 5 mol% MCM-41-bpy-CuI, the cross-coupling reaction of organoboronic acids with diaryl diselenides proceeded smoothly in DMSO/H2O (2/1)

  A高效MCM-41固定联吡啶铜（我）络合物[MCM-41联吡啶翠]从4,4'-双[3-（三乙氧基硅基）丙基氨基] -2,2'-联吡啶制备通过固定上介孔材料MCM-41，然后与CuI反应。在5 mol％MCM-41-bpy-CuI的存在下，有机硼酸与二芳基二硒化物的交叉偶联反应在DMSO / H 2 O（2/1）中于110°C的空气中顺利进行，得到了多种二有机基硒化物，收率好至极好。可以通过简单过滤反应溶液来回收和再循环这种多相铜催化剂，并在不降低活性的情况下，至少进行了10次连续试验。